Effects of Ginkgo biloba extract on biomarker expressions during aflatoxin B1-induced hepatocarcinogenesis in Wistar rats

Tumor

Volumn 30, Issue 1, 2010, Pages 1-5

  Hao, Yan Rong ^a   Ou, Chao ^b   Cao, Ji ^b   Yang, Fang ^b   Duan, Xiao Xian ^b   Yang, Chun ^b   Li, Yuan ^b   Su, Jian Jia ^b  

^a PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

^b Guangxi Cancer Institute   (China)

Author keywords

8 hydroxydeoxy guanosine; AFB1 lysine adducts; Aflatoxin B 1; Ginkgetin; Liver neoplasms, experimental; Plant extracts

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AFLATOXIN B1; ALBUMIN; BIOLOGICAL MARKER; CYTOCHROME P450; DRUG METABOLIZING ENZYME; GINKGO BILOBA EXTRACT; GLUTATHIONE TRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 77954495228     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2010.01.001     Document Type: Article

References (13)

1. KENSLER T W, EGNER P A, WANG J B, et al. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas [J]. Gastroenterology, 2004,127(5 Suppl 1) : S310-S318.
2. PINEAU P, MARCHIO A, BATTISTON C, et al. Chromosome instability in human hepatocellular carcinoma depends on p53 status and aflatoxin exposure [J]. Hutat Res, 2008,653 (1/2) : 6-13.
3. JOHNSON D N, EGNER P A, OBRIAN G, et al. Quantification of urinary aflatoxin B1 dialdehyde metabolites formed by aflatoxin aldehyde reductase using isotope dilution tandem mass spectrometry [J]. Chem Res Toxicol, 2008,21 (3) : 752-760.
4. SIMONICH M T, EGNER P A, ROEBUCK B D, et al. Natural chlorophyll inhibits aflatoxin B1-induced multi-organ carcinogenesis in the rat [J]. Carcinogenesis, 2007,28 (6) : 1294-1302.
5. TANG L, GUAN H, DING X, et al. Modulation of aflatoxin toxicity and biomarkers by lycopene in E344 rats [J]. Toxicol Appl Pharmacol, 2007,219 (1) : 10-17.
6. KAMDEM L K, MEINEKE I, GÖDTEL-ARMBRUST U, et al. Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1 [J]. Chem Res Toxicol, 2006,19 (4) : 577-586.
7. PRIMIANO T, EGNER P A, SUTTER T R, et al. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases [J]. Cancer Res, 1995,55 (19) : 4319-4324.
8. SHEN H M, ONG C N, SHI C Y. Involvement of reactive oxygen species in aflatoxin B1-induced cell injury in cultured rat hepatocytes [J]. Toxicology, 1995,99 (1/2) : 115-123.
9. MUKHERJEE B, DAS T, GHOSH S, et al. Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8- hydroxydeoxyguanosine formation and expressions of c-raf. 1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats [J]. Eur J Cancer Prev, 2007,16 (4) : 363-371.
10. VALAVANIDIS A, VLACHOGIANNI T, FIOTAKIS C. 8-hydroxy-2′- deoxyguanosine (8-OHdG) : a critical biomarker of oxidative stress and carcinogenesis [J] . J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2009,27 (2) : 120-139.